Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. - Wikidata - wikimedia - TriplyDB

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

http://www.wikidata.org/entity/Q44426842

about

The detection, treatment, and biology of epithelial ovarian cancer Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Chemoresistance and targeted therapies in ovarian and endometrial cancers Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Cancer immunotherapy comes of age Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay Potential target antigens for a universal vaccine in epithelial ovarian cancer.Dendritic-cell-based therapeutic cancer vaccines The present status and future prospects of peptide-based cancer vaccines.Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Overcoming immunosuppression to enhance a p53MVA vaccine.Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1.Immunity and immune suppression in human ovarian cancer.Immunotherapeutic approaches to ovarian cancer treatment.Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.Immunotherapy in ovarian cancer.Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Vaccine-based clinical trials in ovarian cancer.Colorectal cancer vaccines in clinical trials.Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.Dendritic cell immunotherapy in ovarian cancer.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Therapeutic targeting of tumor suppressor genes The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Prospect and progress of personalized peptide vaccinations for advanced cancers.Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.

P2860

Q21198791-C8A544A5-A52F-4A81-B6FB-B9128CAD07C6 Q26996829-30D0EAEF-B3CE-4ABA-9694-2B1E476F2815 Q28073246-EB292632-DD71-4D3A-A150-01AC61B03FF9 Q28086993-1C1A7F8D-3FC2-48FB-B768-EA68F62A7DC2 Q29619918-11BFC2B4-E8B8-4A88-BCDA-90290AD51EFF Q30434822-9E49F156-A47E-4755-B8C3-D6A3C9D74ACC Q33750160-4F85B088-B872-499F-B95D-A94618EF1FBA Q33999909-D94CA595-6B25-4375-A804-5556DCFFD12E Q34066932-3F5C3A90-4977-442E-A50D-373FAC065441 Q34159451-FD06ADD3-C812-43DB-9E5B-7766C6CFFD5F Q34360094-F0EEBD51-483F-4273-949B-1BDBB60797F4 Q34528638-F71BB96D-1BBC-4447-B155-65E9236AE360 Q34635795-F5CE22D6-F4EE-45F6-A4EA-397E3253D98D Q34898280-84A6C99B-D5EA-44C0-8B46-3EB928CA0E42 Q34934247-4F36212B-7F2A-4071-B650-DFA4FC4FBAAA Q35108299-9DEDAECC-8FFD-4432-B03D-8AC14EC302EB Q35138135-429618EB-F152-44A6-9C83-056936EFC538 Q35213535-0EDDC9BD-E1CB-4107-B151-23D9D27D79DC Q35214729-0A9E286F-55E8-4E86-AAE0-A26C6ADFEBC3 Q35677112-2E3C2E9F-1037-44AB-91E8-0E8003FB64B2 Q36544827-709E1FF6-780C-4593-8201-7BC126BD7170 Q36631249-3478D328-033D-406A-B971-4C0565646B26 Q36745336-25D50816-59D8-4A5D-8438-7EDDBB69B3E6 Q37224420-B9DD9525-0C3C-427B-8117-22794CEA6E42 Q37477273-FEFB4408-4262-42D5-9742-BF6B19E782A7 Q37791308-6A91F2E4-B106-4B3C-9D8E-898618DB6D4B Q37873932-5C6FB415-37D9-4789-803C-DB016735FD3C Q37892583-00FF90D7-A054-4307-8A04-B8154ED9108B Q37892600-98A01FB3-CDE1-4CE9-A27C-0D81EE2C04B4 Q38059513-4E9DB8D5-98B0-4914-859C-130E49099988 Q38063819-DA306CCD-0F4F-45A5-8B84-EA9CDC950ABC Q38069183-8BA25D9C-90A7-4453-B62C-87564A9BAC4A Q38168904-129D9595-8CA6-4487-948B-02DFDB102D66 Q38174601-F5C64B60-F297-4758-B2C8-C1CF3DF2C3BE Q38293525-5CE78F30-FB83-47FE-A7F7-8237524B2F0F Q38306663-09D96899-C4D2-4398-A985-D507ED972CC1 Q38715211-8E6B96FB-9DEF-4C4D-AF1A-1B65F4C3775E Q38758988-77B6D8FF-0FB1-409E-B174-ABFA21C58D1A Q38764852-AAD79731-4113-42DF-965F-03AA49A44B2C Q40706013-AEC61856-AE98-409C-A597-549986D40500

P2860

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

http://www.wikidata.org/entity/Q44426842

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Immunization with a P53 synthe ...... er patients, a phase II trial.

@en

Immunization with a P53 synthe ...... er patients, a phase II trial.

@nl

type

label

Immunization with a P53 synthe ...... er patients, a phase II trial.

@en

Immunization with a P53 synthe ...... er patients, a phase II trial.

@nl

prefLabel

Immunization with a P53 synthe ...... er patients, a phase II trial.

@en

Immunization with a P53 synthe ...... er patients, a phase II trial.

@nl

P1433

Q44426842-8BFBA6B9-D39E-4C55-9D2A-62CA2689F4ED

P1476

Q44426842-EF5F8F30-617D-4A9A-92A8-878E315FA42F

P2093

Q44426842-025C3DCE-EEF9-4FC2-9752-CF4AB8784209

Q44426842-2A031386-D681-45CE-80CE-7523B914E91A

Q44426842-3A5EA789-EF26-4FD1-A1AC-DE700F768D08

Q44426842-3D2F3F9B-0A54-42C1-B98B-14437026AC3C

Q44426842-50EC4712-415E-4009-8B2A-E424D4AE7CC3

Q44426842-76A0CD96-E39D-45BF-A7D9-F000AB72F207

Q44426842-8EB25339-0ACB-49CE-99D9-DCC307601302

Q44426842-906D5971-9086-4BB7-84FB-32B54CF26198

Q44426842-9554D698-FEC3-4A82-8E07-950ED2BC2E4D

Q44426842-A1AF36D3-26AC-49F9-AB2D-2D5E83C1FF38

P2860

Q44426842-585D37BD-E3A6-457D-B2BD-EC314DFFB7AC

Q44426842-E8D6E4B3-BFA2-47C9-881F-C11E0C848835

P304

Q44426842-47F4E76C-9F8C-4797-8F82-3182F0761798

P31

Q44426842-A094C2D8-E5EC-4014-A2D5-04C8F91E0804

P356

Q44426842-459AB8F4-9EF1-4F37-9E3A-BD49087890FA

P433

Q44426842-5AC5D470-9B12-48D8-AD09-8839A3D314A7

P478

Q44426842-03DA4BDE-BC2D-4643-8118-05A705463601

P50

Q44426842-554FE5F4-C1EC-465E-A67D-97BC7045E410

P577

Q44426842-8C1C2F9A-B297-454C-B5B9-B1BBDB471D4B

P5875

Q44426842-BF5F6611-580B-4EED-9230-B321ADD42ADC

P698

Q44426842-A03268B1-9F95-459E-A9DA-C84353B7FA4B

P921

Q44426842-496BB991-9972-431C-A0C1-FE595D761D30

Q44426842-8B63710C-5CD8-4F32-BFFC-62728A631D72

Q44426842-D5A9670C-7481-4F64-BA59-ED1D2FFC1662

P356

P1433

International Journal of Cancer

P1476

Immunization with a P53 synthe ...... er patients, a phase II trial.

@en

P2093

A Rob P M Valentijn

http://www.w3.org/2001/XMLSchema#string

Annechien J A Lambeck

http://www.w3.org/2001/XMLSchema#string

Ate G J van der Zee

http://www.w3.org/2001/XMLSchema#string

Barbara H W Molmans

http://www.w3.org/2001/XMLSchema#string

Baukje-Nynke Hoogeboom

http://www.w3.org/2001/XMLSchema#string

Bouke G Hepkema

http://www.w3.org/2001/XMLSchema#string

Cornelis J Melief

http://www.w3.org/2001/XMLSchema#string

Hans W Nijman

http://www.w3.org/2001/XMLSchema#string

Harry Hollema

http://www.w3.org/2001/XMLSchema#string

Ineke E Hamming

http://www.w3.org/2001/XMLSchema#string

P2860

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.

The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.

P304

2104-2113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.24597

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26685072

http://www.w3.org/2001/XMLSchema#string

P698

19621448

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial